156 related articles for article (PubMed ID: 37072054)
1. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5.
Molina KC; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
Int J Infect Dis; 2023 Jul; 132():34-39. PubMed ID: 37072054
[TBL] [Abstract][Full Text] [Related]
2. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
3. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
[TBL] [Abstract][Full Text] [Related]
4. Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.
Sridhara S; Gungor AB; Erol HK; Al-Obaidi M; Zangeneh TT; Bedrick EJ; Ariyamuthu VK; Shetty A; Qannus AA; Mendoza K; Murugapandian S; Gupta G; Tanriover B
PLoS One; 2023; 18(4):e0279326. PubMed ID: 37115780
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis.
Liew MNY; Kua KP; Lee SWH; Wong KK
Front Immunol; 2023; 14():1100263. PubMed ID: 37701439
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era.
McCreary EK; Kip KE; Collins K; Minnier TE; Snyder GM; Steiner A; Meyers R; Borneman T; Adam M; Thurau L; Yealy DM; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Open Forum Infect Dis; 2022 Oct; 9(10):ofac517. PubMed ID: 36324319
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
8. Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
Razonable RR; O'Horo JC; Hanson SN; Arndt RF; Speicher LL; Seville TA; Hall ST; Pike ML; Heyliger A; Larsen JJ; Ganesh R; Tulledge-Scheitel SM
J Infect Dis; 2022 Nov; 226(10):1683-1687. PubMed ID: 36124696
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
[TBL] [Abstract][Full Text] [Related]
10. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menachery V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
Cell Rep; 2022 May; 39(7):110812. PubMed ID: 35568025
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
J Infect Dis; 2022 Dec; 226(12):2129-2136. PubMed ID: 35576581
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040
[TBL] [Abstract][Full Text] [Related]
14. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
[TBL] [Abstract][Full Text] [Related]
15. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study.
Kapar A; Xie S; Guo Z; Nan Y; Du Y; Yin X; Gong T; Gu X; Zhou Y; Lu W; Yang A; Luo Z; Dai J; Wang K; Zhao S; Wang K
Expert Rev Anti Infect Ther; 2024 Jun; ():1-9. PubMed ID: 38822541
[TBL] [Abstract][Full Text] [Related]
17. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
[TBL] [Abstract][Full Text] [Related]
18. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Razonable RR; Tulledge-Scheitel SM; Hanson SN; Arndt RF; Speicher LL; Seville TA; Larsen JJ; Ganesh R; O'Horo JC
Open Forum Infect Dis; 2022 Oct; 9(10):ofac411. PubMed ID: 36213724
[TBL] [Abstract][Full Text] [Related]
19. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
20. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
Lo CKL; Lo CKF; Komorowski AS; Leung V; Matic N; McKenna S; Perez-Patrigeon S; Sheth PM; Lowe CF; Chagla Z; Bai AD
BMC Res Notes; 2024 Jan; 17(1):37. PubMed ID: 38267971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
